The organoid technology developed for studying coeliac disease can be adapted and applied to investigate other autoimmune disorders, offering a versatile platform for exploring disease mechanisms and identifying therapeutic targets. By utilizing patient-derived tissues and maintaining the complex interactions between epithelial cells, immune cells, and stromal components in organoids, researchers can create disease-specific models that closely mimic the pathophysiology of various autoimmune conditions. This approach enables the study of immune responses, inflammatory processes, and tissue damage in a controlled and reproducible environment, providing valuable insights into the underlying mechanisms of autoimmune diseases. Furthermore, the organoid technology can be used to screen potential therapeutic compounds, test drug efficacy, and personalize treatment approaches based on individual patient responses. By expanding the application of organoids to different autoimmune disorders, researchers can accelerate the discovery of novel therapeutic targets, improve drug development pipelines, and advance precision medicine strategies for treating autoimmune diseases.